Wedbush Weighs in on Xencor’s Q2 Earnings (NASDAQ:XNCR)

Xencor, Inc. (NASDAQ:XNCR) – Equities researchers at Wedbush reduced their Q2 2025 earnings estimates for shares of Xencor in a research report issued on Wednesday, May 7th. Wedbush analyst D. Nierengarten now forecasts that the biopharmaceutical company will post earnings of ($0.78) per share for the quarter, down from their previous estimate of ($0.60). Wedbush currently has a “Outperform” rating and a $31.00 price target on the stock. The consensus estimate for Xencor’s current full-year earnings is ($3.68) per share. Wedbush also issued estimates for Xencor’s Q3 2025 earnings at ($0.79) EPS, Q4 2025 earnings at ($0.79) EPS, FY2025 earnings at ($3.03) EPS, Q1 2026 earnings at ($0.80) EPS, Q2 2026 earnings at ($0.80) EPS, Q3 2026 earnings at ($0.80) EPS, FY2026 earnings at ($3.20) EPS, FY2027 earnings at ($3.39) EPS, FY2028 earnings at ($4.29) EPS and FY2029 earnings at ($5.95) EPS.

XNCR has been the topic of several other reports. StockNews.com lowered shares of Xencor from a “hold” rating to a “sell” rating in a research report on Friday, March 14th. Barclays reduced their target price on shares of Xencor from $22.00 to $6.00 and set an “underweight” rating on the stock in a research report on Thursday, May 8th. William Blair initiated coverage on shares of Xencor in a research note on Monday, April 21st. They set an “outperform” rating for the company. Finally, Wells Fargo & Company dropped their price target on shares of Xencor from $37.00 to $33.00 and set an “overweight” rating for the company in a research note on Friday, February 28th. Two investment analysts have rated the stock with a sell rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $29.50.

Xencor Stock Performance

NASDAQ:XNCR opened at $8.77 on Monday. The firm’s 50-day moving average is $10.63 and its 200-day moving average is $17.52. Xencor has a 52-week low of $7.16 and a 52-week high of $27.24. The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.23 and a current ratio of 6.23. The company has a market cap of $624.00 million, a price-to-earnings ratio of -2.74 and a beta of 0.99.

Xencor (NASDAQ:XNCR) last announced its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.66) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.06). The firm had revenue of $32.73 million during the quarter, compared to the consensus estimate of $23.44 million. Xencor had a negative return on equity of 30.92% and a negative net margin of 232.77%. The business’s revenue was up 104.6% compared to the same quarter last year. During the same quarter last year, the business earned ($1.11) EPS.

Insider Buying and Selling at Xencor

In other news, EVP Nancy Valente sold 4,616 shares of Xencor stock in a transaction on Friday, May 2nd. The shares were sold at an average price of $11.03, for a total transaction of $50,914.48. Following the transaction, the executive vice president now owns 49,169 shares in the company, valued at approximately $542,334.07. The trade was a 8.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 4.76% of the company’s stock.

Institutional Investors Weigh In On Xencor

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Barclays PLC increased its position in shares of Xencor by 100.7% during the third quarter. Barclays PLC now owns 155,568 shares of the biopharmaceutical company’s stock worth $3,128,000 after acquiring an additional 78,066 shares in the last quarter. Prudential Financial Inc. grew its position in Xencor by 10.7% in the 4th quarter. Prudential Financial Inc. now owns 70,715 shares of the biopharmaceutical company’s stock worth $1,625,000 after purchasing an additional 6,810 shares in the last quarter. Wellington Management Group LLP purchased a new position in Xencor in the fourth quarter valued at about $632,000. Raymond James Financial Inc. purchased a new position in Xencor in the fourth quarter valued at about $2,329,000. Finally, Principal Financial Group Inc. grew its stake in Xencor by 16.5% in the 4th quarter. Principal Financial Group Inc. now owns 340,145 shares of the biopharmaceutical company’s stock valued at $7,817,000 after buying an additional 48,229 shares in the last quarter.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.